CASTLE ROCK, Colo., Aug. 24 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (OTC Bulletin Board: APNB - News) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, announced today the company has accepted an invitation to present at the annual Roth Capital Partners New York Investor Conference to be held September 6th to 7th, 2006. More than 1000 institutional investors are expected to attend the conference, which will be held at the Westin New York at Times Square.
AspenBio Pharma president and CEO, Richard Donnelly, is scheduled to present on Thursday, September 7th, at 8:00 am EST. A simultaneous Webcast will be available at http://www.wsw.com/webcast/roth8/apnb.ob/.
Roth Capital Partners Investor Conferences are among the largest in the nation focused on micro and small-cap companies in the Technology, Healthcare, Financial Services and Consumer Products sectors. For more information on the conference, please visit the conference website at http://rothconference.com, or call the conference desk at 800-678-9147. For media inquiries and press credentials only, call 818-904-0500.
About Roth Capital Partners, LLC
Since 1984, Roth Capital Partners has been a leader and innovator in the small and micro cap markets. Roth provides the full spectrum of investment banking services, including raising capital, research coverage, creating liquidity, trading and market making, merger and acquisition advisory services, sales support, and investor conferences. Visit www.rothcp.com for more information.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and others that have large worldwide market potential. The company was formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation’s largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. The company has created an early pregnancy “open cow” diagnostic for dairy cows that is currently in late-stage development. AspenBio Pharma is also working on a blood test to assist in the diagnosis of appendicitis in humans. For more information, please visit: www.aspenbiopharma.com.
For more information contact: AspenBio Pharma, Inc. Richard Donnelly, CEO 303-794-2000
Investor Relations: Liolios Group, Inc. Scott Liolios or Ron Both 949-574-3860
Source: AspenBio Pharma, Inc.
